TrialBritish journal of clinical pharmacology2022

First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

Stefan Klein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.